Skip to main content
Home > The Daily Extra > Financial News

Chronological Index of BioCentury Extra, The Daily News: Financial News

BioCentury Extra, The Daily News Current Issue
  • FINANCIAL NEWS: Novavax raises $12.2 million

    Vaccines company Novavax Inc. (NASDAQ:NVAX) raised $12.2 million through the sale of 10 million shares at $1.22 in a private placement to RA Capital Healthcare Fund. The price is a 5% premium to Novavax's close of $1.16…

    Published on 5/21/2012
  • FINANCIAL NEWS: Kleiner Perkins launches $525M fund

    Kleiner Perkins Caufield & Byers closed its $525 million KPCB XV fund. The fund will invest in early stage digital consumer and enterprise, green tech and life sciences companies.

    Published on 5/18/2012
  • FINANCIAL NEWS: Tvax pulls IPO

    Cancer company Tvax Biomedical Inc. (Lenexa, Kan.) withdrew its planned IPO, citing market conditions. The company had planned to sell 2 million shares at $9-$11 per share. A $10 price would have raised $20 million and …

    Published on 5/18/2012
  • FINANCIAL NEWS: Kythera files for IPO

    Kythera Biopharmaceuticals Inc. (Calabasas, Calif.) proposed to raise $86.3 million in an IPO underwritten by JPMorgan; Goldman Sachs; Leerink; and Lazard. Kythera's ATX-101 is in Phase III testing to reduce submental (…

    Published on 5/17/2012
  • FINANCIAL NEWS: Ra raises $8.6M in second tranche of series A

    Ra Pharmaceuticals Inc. (Cambridge, Mass.) raised $8.6 million in the second tranche of a planned $27 million series A round. Ra raised $10.3 million in the first tranche in February 2010. New Enterprise Associates led …

    Published on 5/16/2012
  • FINANCIAL NEWS: Arena planning follow-on after panel backs lorcaserin

    Arena Pharmaceuticals Inc. (NASDAQ:ARNA) said late Tuesday it is planning a follow-on underwritten by Jefferies; Piper Jaffray; and BMO Capital Markets. On Thursday, an FDA advisory committee voted 18-4, with one …

    Published on 5/15/2012
  • FINANCIAL NEWS: Cytos raises $32.6 million

    Cytos Biotechnology AG (SIX:CYTN) raised CHF30.4 million ($32.6 million) in an equity and debt financing led by venBio, with participation from Amgen Inc. (NASDAQ:AMGN); Abingworth; and Aisling Capital. The financing …

    Published on 5/15/2012
  • FINANCIAL NEWS: Newron up as Zambon exercises PD option

    Newron Pharmaceuticals S.p.A. (SIX:NWRN) jumped CHF1.50 (37%) to CHF5.51 on Tuesday after Zambon Co. S.p.A. (Bresso, Italy) exercised its option to license exclusive rights to develop and commercialize Parkinson's …

    Published on 5/15/2012
  • FINANCIAL NEWS: Medicis prices $450M note deal

    Medicis Pharmaceutical Corp. (NYSE:MRX) raised $450 million in a bumped-up offering of senior convertible notes. The notes bear 1.375% interest and mature on June 1, 2017. They initially covert at $47.07, which is a 22%…

    Published on 5/14/2012
  • FINANCIAL NEWS: OncoMed files for IPO

    OncoMed Pharmaceuticals Inc. (Redwood City, Calif.) proposed to raise $115 million in an IPO underwritten by Jefferies; Leerink; Piper Jaffray; and BMO Capital Markets. OncoMed's clinical pipeline includes: demcizumab (…

    Published on 5/11/2012
  • FINANCIAL NEWS: Prolor raises $32.5 million in follow-on

    Prolor Biotech Inc. (NYSE-A:PBTH; Tel Aviv:PBTH) raised $32.5 million through the sale of 6.5 million shares at $5 in a follow-on underwritten by Jefferies; Ladenburg Thalmann; and Oppenheimer. The company proposed the …

    Published on 5/11/2012
  • FINANCIAL NEWS: NEA raises $2.1B for new fund

    New Enterprise Associates raised $2.1 billion of a targeted $2.6 billion for its 14th fund, according to an SEC filing. The firm's prior fund, which closed in 2010, was for $2.5 billion. NEA invests in IT, energy …

    Published on 5/10/2012
  • FINANCIAL NEWS: Prolor proposes follow-on

    Prolor Biotech Inc. (NYSE-A:PBTH; Tel Aviv:PBTH) said late Thursday it is planning a follow-on underwritten by Jefferies; Ladenburg Thalmann; and Oppenheimer. Prolor was up $0.06 to $5.69 on Thursday. Prolor's lead …

    Published on 5/10/2012
  • FINANCIAL NEWS: Dynavax prices $74.4M follow-on

    Dynavax Technologies Corp. (NASDAQ:DVAX) raised $74.4 million through the sale of 17.5 million shares at $4.25 in a follow-on underwritten by JPMorgan and Cowen. Dynavax proposed the offering late Tuesday when its stock…

    Published on 5/9/2012
  • FINANCIAL NEWS: Rib-X postpones IPO

    Rib-X Pharmaceuticals Inc. (New Haven, Conn.) postponed its planned IPO, citing market conditions. The move comes a day after the company's latest amendment to the offering. Rib-X hoped to sell 10 million shares at $6-$…

    Published on 5/9/2012
  • FINANCIAL NEWS: Savient raises $44M, restructures debt

    Savient Pharmaceuticals Inc. (NASDAQ:SVNT) said on Wednesday it restructured debt and raised about $44 million through a sale of units comprising notes and warrants. The move comes after the Delaware Court of Chancery …

    Published on 5/9/2012
  • FINANCIAL NEWS: Dendreon falls on 1Q12 results

    Dendreon Corp. (NASDAQ:DNDN) fell $2.94 (25%) to $8.75 on Tuesday after it did not raise its sales outlook for Provenge sipuleucel-T despite reporting 1Q12 sales for the prostate cancer therapy that beat both the Street…

    Published on 5/8/2012
  • FINANCIAL NEWS: Eleven raises $10M in series A extension

    Eleven Biotherapeutics Inc. (Cambridge, Mass.) raised $10 million in an extension of a series A round, bringing the total raised in the round to $45 million. New investor JAFCO joined existing investors Third Rock …

    Published on 5/8/2012
  • FINANCIAL NEWS: Intercell planning EUR 25M financing

    Intercell AG (VSE:ICLL; OTCQX:INRLY) plans to raise EUR 25 million ($32.5 million) in a debt and equity financing from BB Biotech. The financing comprises EUR 20 million ($26 million) in a six-year secured loan that …

    Published on 5/8/2012
  • FINANCIAL NEWS: Rib-X amends IPO

    Rib-X Pharmaceuticals Inc. (New Haven, Conn.) amended its IPO and now hopes to sell 10 million shares at $6-$7 per share. A $6.50 price would raise $65 million and value the company at $129.4 million. Deutsche Bank; …

    Published on 5/8/2012
  • FINANCIAL NEWS: Sutro raises $16.5M in second tranche of series C

    Sutro Biopharma Inc. (South San Francisco, Calif.) raised $16.5 million in the second tranche of a series C round, bringing the total raised in the round to $36.5 million. Skyline Ventures led the tranche, with …

    Published on 5/8/2012
  • FINANCIAL NEWS: Cancer Genetics sets IPO range

    Cancer Genetics Inc. (Rutherford, N.J.) amended its IPO and now hopes to sell 4 million shares at $11-$13 per share. A $12 price would raise $48 million and value the cancer diagnostics company at $111.9 million. …

    Published on 5/7/2012
  • FINANCIAL NEWS: Oxford leverages loans

    Life sciences debt provider Oxford Finance LLC raised $271.4 million by packaging 51 of its loans into bonds sold to third party investors. The bonds pay 3.9% annual interest and have a class A2 rating from Moody's …

    Published on 5/7/2012
  • FINANCIAL NEWS: Belgium-based iTeos debuts to focus on cancer immunotherapy

    Cancer immunotherapy company iTeos Therapeutics S.A. (Gosselies, Belgium) debuted on Thursday with a EUR 3 million ($4 million) series A round from Ludwig Institute for Cancer Research (LICR); Hunza Ventures; Life …

    Published on 5/3/2012
  • FINANCIAL NEWS: Oxford Nanopore raises $51.1 million

    Sequencing company Oxford Nanopore Technologies Ltd. (Oxford, U.K.) raised L31.4 million ($51.1 million) in a private placement to existing investors. Earlier this year, the company unveiled its nanopore single-strand …

    Published on 5/3/2012

< Previous   1  2  3  4  5  Next >
Subscribe Now
Free Trial

About BioCentury

Decision-shaping business intelligence for the global biotech and pharma industry since 1993

Log In


Forgot password  |  Forgot Login


If you are a subscriber, but have forgotten or have never received a password, please go here and ask us to send you a new one.

The Daily Extra

Concise and authoritative news for biotech and pharma, written each business day by BioCentury’s senior editors and analysts.


Find out how to get your biopharma daily news update.